The Privatization Prescription: What Recordati's Delisting Means for Healthcare M&A Recordati, a 100 year old Italian pharmaceutical group, is set to disappear from public markets after a €10.
73 billion cash bid led by CVC Capital Partners and Groupe Bruxelles Lambert was launched. The consortium's offer of €51.
29 per share represents a substantial premium over Recordati's share price, factoring in a recent dividend payment that boosts the total economic package to an implied €52 per share.